Business Daily Media

Times Advertising

.

Anticancer Agent Tazverik Tablets 200mg (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma

  • Written by ACN Newswire - Press Releases

Anticancer Agent Tazverik Tablets 200mg (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma

TOKYO, Jun 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide) in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not

Read more //?#

PayNuts Unveils Expanded Integrated Solutions and Refreshed Brand to Support Australian SMEs

PayNuts, one of Australia’s fastest-growing payment service providers, has unveiled a refreshed brand identity and an expanded suite of integrated b...

BizCover Brings Australia’s First AI-Based Insurance Quotes to ChatGPT

Australian small business owners can now receive and compare business insurance quotes directly inside ChatGPT, in a move that signals a major shi...

VistaPrint Research Reveals Australian Small Businesses Face a Succession Cliff

With only 16% of retiring small businesses having a succession plan, tens of thousands risk closure as one in three owners nears retirement.  Ne...

Corporate volunteering grows up: how companies are shifting to meaningful, community-led impact

As workplaces settle into the new year and look for ways to strengthen culture, capability and connection, experts say corporate volunteering is e...

The Rise of Mobile-First Venues

Global Hospitality Platform, Tabit, Reveals Five Ways to Maximise Benefits of Mobile-First Systems  As Australian hospitality venues grapple with...

Why the SME is now the primary engine of global cybercrime

For over a decade, the most practical and effective advice we could offer an employee was to spot the typo. It was practical, it was free, and it wo...